Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could custom blood pressure goals save more hearts?

NCT ID NCT07345559

Disease control Sponsor: CMC Ambroise Paré Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Cardiogenic shock is a life-threatening condition where the heart can't pump enough blood. This study tests whether setting a personalized blood pressure target based on central venous pressure improves survival and reduces organ damage compared to the standard fixed target. About 400 adults in cardiogenic shock will be randomly assigned to either personalized or standard blood pressure management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized blood pressure management
What this could lead to
If successful, this could lead to a new standard for managing blood pressure in cardiogenic shock, potentially reducing deaths and organ failure.
What could go wrong
This is a mid-sized trial testing a strategy, not a new drug. The benefit may be small or not apply to all patients, and the approach requires invasive monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 406 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years * Cardiogenic shock state, according to the consensus definition, * SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C * Consent from the patient or close relative / trusted person or emergency inclusion procedure * Benefiting fromciary of a social security scheme Exclusion Criteria: * Catecholamine infusion for more than 24 consecutive hours; * CVP \< 5 mm Hg at inclusion; * MAP \> 70 mmHg at inclusion; * Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion; * Chronic dialysis or presence of renal replacement therapy criteria at inclusion ; * Recovered cardiopulmonary arrest within 7 days prior to inclusion; * Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded); * Primary diagnosis of tamponade, pulmonary embolism, or septic shock; * Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations; * Absence of central venous access; * Known pregnancy or current breastfeeding; * Under legal guardianship, curatorship, or judicial protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67000, France

  • CHU d'Amiens-Picardie

    NOT_YET_RECRUITING

    Amiens, 80000, France

  • CHU d'Orléans

    NOT_YET_RECRUITING

    Orléans, 45100, France

  • CHU de Toulouse

    NOT_YET_RECRUITING

    Toulouse, 31000, France

  • CMC Ambroise Paré - Hartmann

    RECRUITING

    Neuilly-sur-Seine, 92200, France

  • Centre Cardiologique du Nord

    NOT_YET_RECRUITING

    Saint-Denis, 93200, France

  • Clinique NCT + /Saint-Gatien

    NOT_YET_RECRUITING

    Saint-Cyr-sur-Loire, 37540, France

  • Hôpital Cochin

    NOT_YET_RECRUITING

    Paris, 75014, France

  • Hôpital Henri Mondor

    NOT_YET_RECRUITING

    Créteil, 94010, France

  • Hôpital Lariboisière

    NOT_YET_RECRUITING

    Paris, 75010, France

  • Hôpital Privé Jacques Cartier

    NOT_YET_RECRUITING

    Massy, 91300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.